The US FDA’s approvals of Amgen Inc.’s Blincyto and EMD Serono Inc./Pfizer Inc.’s Bavencio using external control arms could mark a tipping point in the regulatory use of real-world evidence (RWE).
FDA has turned has turned to RWE – mostly in the form of historical control arms or case studies –...